Rapid Information on OLM No 216 140430.docVIP

Rapid Information on Olmesartan and other ARBs No.216 2014/04/30 　　　　　　　　　　　　　　　　　 　　　　　　　　　Be the first to know! 　　　 　 　　 (Toru Komai, Ph.D.) 216-1: The findings from acute myocardial infarction (AMI) model mice suggests that earlier administration of olmesartran in patients with AMI is a potential preventive approach for cardiac rupture. Title：Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and P53. 2-3 216-2: In patients with moderate-to-severe hypertension, long-term treatment with OLM/AML/HCTZ triple combination therapy was well tolerated and effective. Title：Open-Label Study Assessing the Long-term Efficacy and Safety of Triple Olmesartan/Amlodipine/Hydrochlorothiazide Combination Therapy for Hypertension. 4 216-3：Patients treated with ACEI had significantly lower long-term mortality compared with those treated with ARB from 2 to 5 years after AMI. Title：Comparison of 5-Year Survival After Acute Myocardial Infarction Using Angiotensin Converting Enzyme Inhibitor versus Angiotensin II Receptor Blocker 5 Abbreviations: BP: blood pressure, SBP/DBP: systolic/ diastolic BP, RAS: renin–angiotensin system, Ang II: angiotensin II, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker, ACE-I: angiotensin converting enzyme inhibitor, OLM: olmesartan, AML: amlodipine, HCTZ: hydrochlorothiazide, CVD: cardiovascular disease, CHF: chronic heart failure, CKD: chronic kidney disease, 216-1: The findings from acute myocardial infarction (AMI) model mice suggests that earlier administration of olmesartran in patients with AMI is a potential preventive approach for cardiac rupture. Cardiac rupture is a catastrophic complication for patients with acute myocardial infarction (MI). The incidence of cardiac rupture is 1 – 6% a